Kaneka Ubiquinol Wins Award at FFWS 2024

Kaneka Corporation, the global leader in the scientific research and manufacture of the evidence-based potent antioxidant Ubiquinol, is thrilled to announce its prestigious win of the "Annual Ingredient Cardiovascular Health Award" at Functional Foods for Wellness Summit (FFWS 2024) Industry Awards, held in Kuala Lumpur on 6 March 2024. 

FFWS is a leading healthcare professional summit, committed to practitioner education with the FFWS Awards honouring enterprises and products in the Asia-Pacific region that demonstrate outstanding achievements or significant contributions to the areas of functional food and dietary supplements.

The FFWS Annual Ingredient Cardiovascular Award recognises Kaneka Ubiquinol's significant contribution to supporting cardiovascular health with over 45 years of scientific research, 90+ studies and 80+ patents supporting its rigour, innovation and excellence in precision manufacturing quality in the quest to support optimal cardiovascular health for millions across the region.

Tsuyoshi Takakuwa, Head of Marketing and Sales at Kaneka, expressed his gratitude and excitement over the win: "We are deeply honoured to receive this distinguished award from FFWS. It is a testament to our commitment to providing high-quality, evidence-based bioidentical Ubiquinol that supports cardiovascular health and overall wellbeing.”

“The recognition by the FFWS judges fuels our passion to continue innovating and contributing to the health of individuals worldwide. We thank you all."

Kaneka Ubiquinol is scientifically proven to support mitochondrial function throughout each cell in the body for multiple functions including cardiovascular health and the maintenance of healthy cardiovascular function, supporting blood vessel health and healthy LDL cholesterol, amongst many other.

According to statistics on causes of death in Malaysia 2022 researched by the Department of Statistics Malaysia[i], ischemic heart disease was the second highest cause of death in Malaysia with 13.7% after Covid-19 infection deaths.

In Australia in 2020, there were an estimated 56,700 acute coronary events among people aged 25 and over – equivalent to around 155 events every day. In 2021, coronary heart disease was the underlying cause of 17,300 deaths (10% of all deaths), according to Australian Institute of Health and Welfare statistics.[ii]

Multiple studies have shown that supplementing with Kaneka Ubiquinol has led to significant improvement in peripheral endothelial function in patients with heart failure with reduced ejection fraction (HFrEF)[iii] and other cardiovascular [iv]

Crafted through a unique patented yeast fermentation process and embodying precision Japanese manufacturing, Kaneka Ubiquinol has set a new standard in the nutrition and functional food industry as best-in-class, supporting overall mitochondrial health that impacts the entire body.

The FFWS Industry Awards ceremony, which took place on 6 March 2024 at the Wyndham Grand Bangsar, Kuala Lumpur, marks a significant milestone for Kaneka Ubiquinol in its mission to support optimal health through advanced evidence-based supplementation.

The Malaysian Dietary Supplement Association (MADSA) Council congratulates our member Kaneka for this great achievement. We look forward to Malaysian residents improving their cardiovascular health and easing the disease burden of the country and the financial expenditure of the government.

For more information about Kaneka Ubiquinol and its benefits, please visit https://www.ubiquinol.net.au/.